Targeting CTORC complexes suppresses the growth of primitive human AML progenitors in vitro and elicits strong antileukemic responses in AML xenografts in vivo.47 4) Other hematological malignancies (including CLL, diffuse large B-cell lymphoma [DLBCL], MM, and NK-cell leukemia) have also been demonstrated to respond to CDK9 inhibitors.49,50,52–54. Here, CDK9 is linked to hematologic disorder.